InvestSMART

Antisense Therapeutics Limited (ASX: ANP) - Announcements

Current share price for ANP : $0.058 0.003 (4.92%)+

ASX company news and announcements for Antisense Therapeutics Limited (ANP) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Antisense Therapeutics Limited (ANP) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Antisense Therapeutics Limited (ANP), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Antisense Therapeutics Limited (ANP)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$52 Trading Halt 14 May 2015 9:05AM $0.150 $0.058 fallen by 61.33%
$52 Appendix 4C - quarterly 30 Apr 2015 9:40AM $0.145 $0.058 fallen by 60%
$52 ATL1103 New European Patent Application Allowance 16 Apr 2015 8:57AM $0.105 $0.058 fallen by 44.76%
$52 Company Update 13 Apr 2015 2:14PM $0.080 $0.058 fallen by 27.50%
$52 ATL1103 Higher Dose Study to Support Phase III to Commence 5 Mar 2015 10:01AM $0.097 $0.058 fallen by 40.21%
$52 Half Yearly Report and Accounts 25 Feb 2015 7:14PM n/a $0.058 n/a
$52 Appendix 4C - quarterly 23 Jan 2015 8:45AM $0.099 $0.058 fallen by 41.41%
$52 Ethics Committee Approves Higher Dose ALT1103 Study 22 Dec 2014 8:31AM $0.090 $0.058 fallen by 35.56%
$52 Company Update 9 Dec 2014 9:39AM $0.095 $0.058 fallen by 38.95%
$52 Appendix 4C - quarterly 30 Oct 2014 9:38AM $0.105 $0.058 fallen by 44.76%
$52 ATL1102 for MS FDA Response to Phase IIb Study Plans 24 Oct 2014 1:22PM $0.110 $0.058 fallen by 47.27%
$52 Trading Halt 24 Oct 2014 9:33AM $0.105 $0.058 fallen by 44.76%
$52 Receipt of $1.14 million R&D Tax Incentive payment 15 Oct 2014 9:18AM $0.100 $0.058 fallen by 42%
$52 Share Purchase Plan Underwritten 26 Sep 2014 12:49PM $0.120 $0.058 fallen by 51.67%
$52 Placement and Share Purchase Plan 25 Sep 2014 9:40AM $0.120 $0.058 fallen by 51.67%
$52 Trading Halt 23 Sep 2014 12:33PM $0.145 $0.058 fallen by 60%
$52 ATL1102 Phase II MS trial results published in NEUROLOGY 22 Sep 2014 9:39AM $0.140 $0.058 fallen by 58.57%
$52 ATL1102 for MS further development plans 16 Sep 2014 9:57AM $0.140 $0.058 fallen by 58.57%
$52 ATL1103 Phase II Trial - Successful Efficacy Results 3 Sep 2014 9:10AM $0.150 $0.058 fallen by 61.33%
$52 Trading Halt 1 Sep 2014 8:45AM $0.150 $0.058 fallen by 61.33%
$52 Appendix 4E and Full Year Audited Statutory Accounts 25 Aug 2014 9:05AM $0.140 $0.058 fallen by 58.57%
$52 Strategy Update - ATL1103 & ATL1102 19 Aug 2014 8:58AM $0.140 $0.058 fallen by 58.57%
$52 Appendix 4C - quarterly 31 Jul 2014 1:04PM $0.135 $0.058 fallen by 57.04%
$52 ATL1102 for Stem Cell Mobilisation Trial Results 23 Jul 2014 9:29AM $0.130 $0.058 fallen by 55.38%
$52 Allowance of Canadian Patent on ATL1103 & Development Update 7 Jul 2014 9:56AM $0.135 $0.058 fallen by 57.04%

476 - 500 of 707 results

Page 20 of 29

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.